Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525147 | 0.84 | ALDH1A1 (0.59) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL2075032 | 0.84 | ALDH1A1 (0.59) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL15525132 | 0.84 | ALDH1A1 (0.59) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL4172293 | 0.81 | ALDH1A1 (0.52) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL20451992 | 0.81 | ALDH1A1 (0.52) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL2075811 | 0.81 | ALDH1A1 (0.52) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL18454013 | 0.79 | ALDH1A1 (0.48) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL20452492 | 0.79 | ALDH1A1 (0.48) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL18453946 | 0.78 | ALDH1A1 (0.56) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL18453947 | 0.78 | ALDH1A1 (0.56) | RAB9AALDH1A1SMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-04-30 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| EP-3331880-B3 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-01-11 | — | — | EP | disclosed |
| US-20220267315-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2022-08-25 | — | — | US | disclosed |
| EP-3957637-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Therapeutics Pty Ltd (AU) | 2022-02-23 | — | — | EP | disclosed |
| EP-3331880-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-12-01 | — | — | EP | disclosed |
| CN-113336746-A | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108349964-B | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| US-20160068497-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | RAB9A 4119/4885ALDH1A1 3569/4885SMN1; SMN2 1088/4885 |
| US-20160068497-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | RAB9A 4062/4885ALDH1A1 740/4885SMN1; SMN2 1957/4885 |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | RAB9A 4105/4885ALDH1A1 3547/4885SMN1; SMN2 1063/4885 |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK2 | RAB9A 4119/4885ALDH1A1 3569/4885SMN1; SMN2 1088/4885 |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDKL2 | RAB9A 4139/4885ALDH1A1 3585/4885SMN1; SMN2 1032/4885 |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK3 | RAB9A 4381/4885ALDH1A1 3706/4885SMN1; SMN2 1792/4885 |
| US-20220267315-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK3 | RAB9A 4381/4885ALDH1A1 3706/4885SMN1; SMN2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.